Cholesterol ratio and kidney disease risk in diabetes
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether the ratio of two types of cholesterol (non-HDL to HDL) is linked to kidney damage in people with diabetes. It aims to help identify those at higher risk for diabetic kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with diabetes (Type 1 or Type 2)
- You may or may not have diabetic kidney disease
- You are willing to join the study and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether vitamin D levels are linked to cholesterol and other blood fats in adults with type 2 diabetes who are obese. It may help understand if vitamin D plays a role in managing heart health.
This study looks at whether certain proteins in your blood can help detect kidney damage earlier in people with type 2 diabetes. It aims to find better ways to monitor kidney health and potentially prevent or delay diabetic kidney disease.
This study checks cholesterol and fat levels in the blood of people with chronic kidney disease, comparing those with and without diabetes. It aims to understand how kidney disease affects lipid profiles.
This study looks at two simple blood test ratios (uric acid/HDL and monocyte/HDL) to see if they can help predict diabetes-related complications. It may give doctors a new way to catch problems early.
This study looks at how well we can predict heart and kidney problems in people who have both coronary heart disease and chronic kidney disease. By analyzing certain markers, researchers hope to create a better risk assessment tool.
This trial looks at how likely heart failure is for people who have both chronic kidney disease and type 2 diabetes. It aims to better understand and predict risk.
Hear when a new Dyslipidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.